BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23238896)

  • 1. Clinical analysis and prognostic significance of lymphoma-associated hemophagocytosis in peripheral T cell lymphoma.
    Xie W; Hu K; Xu F; Zhou D; He J; Shi J; Luo Y; Zhu J; Zhang J; Lin M; Ye X; Huang H; Cai Z
    Ann Hematol; 2013 Apr; 92(4):481-6. PubMed ID: 23238896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome.
    Tong H; Ren Y; Liu H; Xiao F; Mai W; Meng H; Qian W; Huang J; Mao L; Tong Y; Wang L; Qian J; Jin J
    Leuk Lymphoma; 2008 Jan; 49(1):81-7. PubMed ID: 18203016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China.
    Tong H; Ren Y; Qian W; Xiao F; Mai W; Meng H; Jin J
    Int J Hematol; 2009 Oct; 90(3):303-310. PubMed ID: 19728028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
    Liang X; Guo L; Hu X; Li S; Wen S
    Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
    Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aggressive peripheral T-cell lymphomas: 2013.
    Armitage JO
    Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
    Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
    Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone.
    Suzuki K; Terui Y; Nakano K; Nara E; Nasu K; Ueda K; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Takahashi S; Hatake K
    Leuk Lymphoma; 2012 May; 53(5):849-54. PubMed ID: 22035416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
    Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
    Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
    Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS.
    Cao Z; Wang X; Xue X; Feng X
    Ann Hematol; 2024 Mar; 103(3):869-883. PubMed ID: 38040859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
    Armitage JO
    Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
    Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified.
    Kim HD; Cho H; Sohn BS; Park CS; Huh J; Ryu JS; Lee SW; Yoon SE; Kim SJ; Ko YH; Kim WS; Suh C
    Leuk Lymphoma; 2022 Jan; 63(1):124-130. PubMed ID: 34702115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
    Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
    Kriachok I; Tytorenko I; Shudrak N; Aleksik O; Stepanishyna Y; Kadnikova T; Pastushenko Y; Shokun N; Rudiyk T; Bushuieva M
    Exp Oncol; 2024 Feb; 45(4):474-482. PubMed ID: 38328842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis.
    Tolkachjov SN; Weenig RH; Comfere NI
    J Am Acad Dermatol; 2016 Nov; 75(5):992-999. PubMed ID: 27498959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution.
    Broussais-Guillaumot F; Coso D; Belmecheri N; Ivanov V; Schiano de Collela JM; Aurran-Schleinitz T; Stoppa AM; Chetaille B; Xerri L; Esterni B; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2013 Nov; 54(11):2392-8. PubMed ID: 23410100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
    Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
    Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.